Add BrightSurf on Google Email

HKUMed discovers a novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus associated immune suppression Leads to potential therapeutic targets

Researchers at HKUMed identified a new type of nasopharyngeal carcinoma associated with EBV and immunosuppression in the tumor microenvironment. Global DNA hypermethylation was found to be a critical step in NPC pathogenesis, while global DNA hypomethylation may lead to immune evasion.

SourceThe University of Hong Kong·JournalEBioMedicine·TypeExperimental study·DateDec 15, 2022

Exercise is medicine for cancer and every dose counts - even in late stages in the disease

A new study from Edith Cowan University found that a single bout of exercise can significantly suppress tumour growth in people with late-stage prostate cancer. The researchers observed increased levels of anti-cancer myokines after high-intensity exercise, which helped fight cancerous cells and stimulated anti-cancer processes.

SourceEdith Cowan University·JournalProstate Cancer and Prostatic Diseases·TypeObservational study·DateDec 13, 2022

A double bind for cancer

Researchers found that simultaneously targeting two signalling switches can severely inhibit tumour angiogenesis, cancer growth and metastasis in multiple models of cancer. This approach has the potential to restrict a cancer's ability to escape therapy by rapidly destroying the VEGF receptor when both receptors are targeted.

SourceUniversity of East Anglia·JournalCancer Research Communications·TypeExperimental study·DateDec 12, 2022

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateDec 10, 2022

Structural studies offer “how-to” guide for designing cancer drugs

Researchers have discovered the three-dimensional structure of phosphoinositide 3-kinase alpha (PI3Kα) and how it changes with cancer-associated mutations. This knowledge enables the design of targeted drugs that can specifically bind to mutated versions, potentially eliminating side effects associated with current PI3Kα inhibitors.

SourceScripps Research Institute·JournalProceedings of the National Academy of Sciences·DateDec 9, 2022

Click release of nitrite

A team of researchers has developed a bioorthogonal molecular system that selectively transports nitrite ions to the endoplasmic reticulum, where they are released, triggering cell death in cancer cells. The system demonstrates synergistic effects with various cancer therapy drugs.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateNov 25, 2022

Researchers identify how certain immune cells contribute to worse survival in patients with HER2-positive breast cancer

Researchers found that HER2-positive breast cancer patients with high levels of tumour infiltrating lymphocytes in residual disease have significantly shorter overall survival. High levels of TILs are associated with poorer outcomes, while lower levels are linked to improved survival rates.

Ultrasound-guided surgery is quicker, less painful and more effective for treating early form of breast cancer

Researchers at Clinica Universidad de Navarra found that ultrasound-guided surgery (IOUS) is more effective and quicker than traditional wire-localisation methods for treating ductal carcinoma in situ (DCIS). This technique reduces the risk of positive margins, a common cause of second operations.

The X chromosome is silenced in some male cancers

Researchers discovered that X chromosome is actively silenced in about 4% of male cancer samples, a phenomenon previously seen only in female cells. This finding could lead to new insights into the development and treatment of various types of cancers.

SourceCell Press·JournalCell Systems·TypeMeta-analysis·DateNov 9, 2022

Extracellular viscosity linked to cancer spread

Researchers found that cancer cells can migrate faster in higher viscosity environments due to the formation of denser actin networks and cooperative signaling pathways. This discovery provides a new framework for understanding metastasis and may lead to the identification of potential targets to combat cancer spread.

SourceJohns Hopkins Medicine·JournalNature·DateNov 2, 2022

Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer: first results from ARROS-1 phase I clinical trial

In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 28, 2022

Experimental drug to treat liver cancer shows evidence of activity with manageable side effects

A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 27, 2022

Overcoming resistance to colon cancer treatment

Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.

SourceUniversité de Genève·JournalCancers·TypeNews article·DateOct 27, 2022

Moffitt researchers discover connection between stress-activated signaling and immune cell evasion in melanoma

Researchers found that high PERK activity correlates with poorer outcomes and lower anti-tumor immune cells in patients with melanoma. Inhibition of PERK promoted a type of cell death called paraptosis, which involved trafficking of immune cells to tumors and matured dendritic cells triggering anti-tumor T cell immunity.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalCancer Cell·TypeExperimental study·DateOct 10, 2022

New insights into tumor biology

A recent study reveals that cancer cells adopt a softer state to facilitate metastasis, forming a new mechanical state with rigid islands in a fluid environment. This state allows tumors to grow while providing room for soft, motile cells to break out and form metastases.

SourceUniversität Leipzig·JournalNature Physics·TypeExperimental study·DateOct 4, 2022

Disarming the body’s defenders

A study published in Science reveals that tumor cells with a specific mutation release a chemical metabolite that weakens nearby immune cells, rendering them less capable of killing cancer cells. The findings highlight the critical role of the tumor microenvironment in cancer growth and provide insights into developing targeted therapi...

SourceHarvard Medical School·JournalScience·DateSep 29, 2022

Machine learning creates opportunity for new personalized therapies

Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.

SourceMichigan Medicine - University of Michigan·JournalNature Metabolism·TypeExperimental study·DateSep 28, 2022

Researchers decipher the mechanism that enables skin cancer to metastasize to the brain - and inhibited its spread by 80%

Tel Aviv University researchers discovered that skin cancer cells interact with astrocytes in the brain, promoting metastasis. By inhibiting this interaction using existing treatments, they delayed the spread of melanoma to the brain by 60-80%. This breakthrough has implications for treating advanced-stage melanoma.

SourceTel-Aviv University·JournalJCI Insight·DateSep 20, 2022